title: Proteoglycans on bone tumor development.
abstract: Proteoglycans, extracellular matrix components, exert several activities on bone cells and seem crucial for maintaining an appropriate number of osteoblasts and osteoclasts. The overall data strengthen a pro-bone resorptive role for proteoglycans, through the control of osteoprotegerin availability and of receptor activator of NF-kappaB ligand bioactivity. In parallel, proteoglycans participate in the control of tumor development at different levels, including bone tumor development and bone metastases dissemination. This dual role makes them good candidates as regulatory molecules in the vicious cycle between tumor proliferation and bone resorption observed during tumor development in bone site. Knowledge of the biological roles of these molecules in cancer biology, tumor angiogenesis and metastasis has promoted the development of drugs targeting them.
authors.affiliation: Université de Nantes, France.
authors.forename: Carmen Ruiz
authors.initials: CR
authors.lastname: Velasco
authors.forename: Sylvia
authors.initials: S
authors.lastname: Colliec-Jouault
authors.forename: Françoise
authors.initials: F
authors.lastname: Redini
authors.forename: Dominique
authors.initials: D
authors.lastname: Heymann
authors.forename: Marc
authors.initials: M
authors.lastname: Padrines
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D001862:Bone Resorption / Q000188:drug therapy; D001842:Bone and Bones / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology*; D049109:Cell Proliferation / Q000187:drug effects; D015195:Drug Design; D006801:Humans; D011509:Proteoglycans / Q000037:antagonists & inhibitors* / Q000502:physiology*
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D011509:Proteoglycans